Firma lehnt den SF Express -Anteil ab, Ziele für den Börsengang mit einem Einsatz von 600 Mio. Einnahmen, 6B Bewertung
Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. (hereinafter referred to as "Shanghai Shengsheng") is a professional cold chain service provider for biopharmaceuticals and a pioneer in China's biopharmaceutical cold chain service industry. Since its establishment, the company has been focusing on providing full-chain integrated cold chain services for customers in drug research and development, life sciences, Biotechnologie, and commercial finished pharmaceuticals. With over a decade of professional experience and technical accumulation, Shanghai Shengsheng continuously innovates, leading and shaping the industry's practice models and service standards. On June 30th of this year, Shanghai Shengsheng submitted its listing materials and received acceptance, aiming for an IPO on the main board of the Shanghai Stock Exchange. On July 28th, it received the first round of inquiries, but as of now, the company has not yet responded. The company's listing sponsor is China International Capital Corporation (CICC). Am September 30, 2023, due to the financial information recorded in the application documents for issuance...
